Home > Insider Trading > Filing (0001127602-23-012463)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1878313	Maia Biotechnology Inc.	MAIA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1913257	Vlad Vitoc	444 West Lake Street, Chicago IL 60606	Chief Executive Officer	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-04-03	1,375	$3.50	804,196	No	4	P	Direct
Common Stock	Acquisiton	2023-04-04	925	$3.56	805,121	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	210,000	Indirect	See Footnote

Footnotes

These securities are beneficially owned by Mr. Vitoc's spouse. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Vitoc that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended.
The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.45 to $3.60, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.53 to $3.60, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.